PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
Retrieved on:
Tuesday, October 24, 2023
Fungal infection, Stroke, Phage therapy, Staphylococcus aureus, Incidence, National Agency for Food and Drug Administration and Control, Heart, Medication, Teaching hospital, Hope, Mortality, Endocarditis, Safety, ANSM, Infection, CEST, Pharmacokinetics, Endocardium, Clinical trial, S. aureus, Jean-Pierre du Teil, Bacteria, Blood, S, Therapy, Patient, Heart failure, CPP, Pharmaceutical industry
Endocarditis is an infection of the endocardium (inner lining of the heart) and valves, usually caused by bacteria.
Key Points:
- Endocarditis is an infection of the endocardium (inner lining of the heart) and valves, usually caused by bacteria.
- The main cause of endocarditis infections, S. aureus, is responsible for around 30%1 of cases.
- Pascal Birman, Chief Medical Officer of PHAXIAM Therapeutics, stated: "This phase 1 study was designed primarily to assess the safety and pharmacokinetics of our anti-S. aureus phages in the treatment of endocarditis infections.
- The treatment of endocarditis infections caused by S. aureus using phage therapy could thus offer a major alternative and hope to many patients who have reached a therapeutic impasse.”